CD4 and lung cancer: Conversely, RFA reportedly causes a decrease in circulating CD4+ CD25+ Foxp3+ immunosuppressive regulatory T cells (Treg) 30 days post treatment in lung cancer patients which is noteworthy since Treg counteract the function of cytotoxic CD8+ effector T cells [6, 28].